ACE-031

Also known as Ramatercept, ACVR2B-Fc, ActRIIB-Fc, ActRIIB-IgG1

An ActRIIB-Fc decoy receptor (ramatercept) that traps myostatin and related ligands to increase muscle mass; clinical development was halted over vascular safety signals.

Molecular weight~90 kDa (glycosylated homodimer; ~45 kDa per ActRIIB-Fc monomer)

Half-life~10–15 days (Fc-fusion; estimated from clinical pharmacokinetics)

CategoryGrowth & GH

Typical use cases

✓ Myostatin pathway research✓ Muscle mass/strength studies✓ Muscle-wasting disease models✓ Bone density research

Dosing guidelines

StartingResearch context: ~0.5–1 mg/kg every 2–4 weeks (clinical trials used 0.02–3 mg/kg IV/SC); no established consumer protocol.

Maintenance~1 mg/kg every 2–4 weeks (highly approximate; not standardized).

Max (studied)Clinical trials explored up to ~3 mg/kg; higher exposure correlated with vascular bleeding events — treat any figure as an upper research bound only.

Titration

Typically flat-dosed at long intervals due to the multi-day half-life; no validated titration scheme exists.

Reconstitution

1 mg vial: add ~1–2 mL bacteriostatic water and swirl gently (do not shake) for ~0.5–1 mg/mL.

Injection sites

Subcutaneous (abdomen/thigh), rotate sites; clinical trials used SC and IV routes.

Storage & handling

Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).

Side effects

Epistaxis (nosebleeds) Moderate · Common
Skin telangiectasia (dilated capillaries) Mild · Common
Gingival/mucosal bleeding Mild · Uncommon
Headache Mild · Common
Serious vascular bleeding events Severe · Rare

Research summary

ACE-031 is a soluble fusion of the activin receptor type IIB (ACVR2B) extracellular domain and an IgG1 Fc region; it acts as a ligand trap for myostatin (GDF8), activin, and GDF11, de-repressing muscle growth. A Phase 1 single-dose study in healthy postmenopausal women reported gains in lean mass and thigh muscle volume, and a Phase 2 trial was run in Duchenne muscular dystrophy. Development was halted (2011) and discontinued (2013) after off-target trapping of BMP9/BMP10 produced vascular events — nosebleeds, gingival bleeding, and skin telangiectasia. Human safety data therefore exist but the program was abandoned; current material is research-grade only. Educational only — not medical advice.

Key references

Attie et al., Muscle & Nerve (2013) — single-dose Phase 1 of ACE-031 in healthy postmenopausal women
Campbell et al., Muscle & Nerve (2017) — Phase 2 ACE-031 in Duchenne muscular dystrophy

Related compounds

Follistatin 344 → Myostatin (GDF8) YK-11

Where to buy

🛍 Core Peptides Third-party tested ↗

These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.

Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.

Track ACE-031 in DoseForge

Log doses, rotate sites, watch your progress — free.

Get the app